Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows antibiotic treatment does not reduce risk of secondary cardiac events

21.04.2005


Taking antibiotics weekly for a year does not reduce the risk of a heart attack or other cardiac event for patients with stable coronary artery disease, according to a University of Washington study. The study was published in the April 22 edition of the New England Journal of Medicine.

Previous studies have found the bacteria Chlamydia pneumoniae in the arterial plaque of patients with coronary artery disease. Some doctors have reasoned that removal of C. pneumoniae from the system could reduce the risk of subsequent cardiac events. Prescription of antibiotics for this purpose had not been tested through a randomized clinical trial. The investigation of whether antibiotics could be used to treat the bacteria, and therefore reduce the risk of cardiac events, was conducted at 27 different sites in the United States.

All U.S. adults have been exposed to C. pneumoniae, which spreads through the air and causes pneumonia or mild repiratory disease, at some point in their lives.



This study, called the Azithromycin coronary events study, or ACES, found no benefit from treating the C. pneumoniae bacteria with an antibiotic in order to reduce the risk of heart attack or improve overall cardiac outcomes.

ACES researchers randomly assigned 4,012 men and women to receive either once-weekly doses of Azithromycin or a placebo for one year, starting in 1999. After an average follow-up of 3.9 years, there was no significant reduction of cardiac events, defined as death, heart attack, unstable angina, angioplasty or cardiac surgery, among participants receiving antibiotic compared to those given placebo. This lack of antibiotic effect was shown for all participants, regardless of age, gender, smoking status, or presence of C. pneumoniae antibody. The antibiotic treatment also had no effect on total mortality or on incidence of stroke.

Men and women were included in the study if they had stable coronary artery disease following a previous cardiac event such as a heart attack, angioplasty or cardiac bypass surgery. Azithromycin was selected because of its proven effectiveness against the C. pneumoniae bacteria and for its once-weekly dosing.

"This is conclusive evidence against using antibiotics to treat late stages of cardiovascular disease, but since the trial was not designed to study the role of C. pneumoniae in causing coronary heart disease, the ACES results do not tell us anything about a possible role of C. pneumoniae in the early development or acceleration of disease in the coronary arteries," said the study’s principal investigator, Dr. J. Thomas Grayston, professor of epidemiology in the University of Washington School of Public Health and Community Medicine. "More study is needed to determine the role of C. pneumoniae in heart disease."

Justin Reedy | EurekAlert!
Further information:
http://www.washington.edu

More articles from Studies and Analyses:

nachricht Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Touch Displays WAY-AX and WAY-DX by WayCon

27.06.2017 | Power and Electrical Engineering

Drones that drive

27.06.2017 | Information Technology

Ultra-compact phase modulators based on graphene plasmons

27.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>